CANCER TREATMENT METHODS BASED ON TP53 MUTATION STATUS AND HYPERMUTATION STATUS

• 1. 基于TP53突变状态和超突变状态的癌症治疗方法 [P] . 中国专利： CN112513296A . 2021-03-16
• 2. 通过NRF2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法 [P] . 中国专利： CN109890982A . 2019-06-14
• 3. CANCER TREATMENT METHODS BASED ON TP53 MUTATION STATUS AND HYPERMUTATION STATUS [P] . EP3810810A1 . 2021-04-28

  机译： 基于TP53突变状态和超岩地位的癌症治疗方法

• 4. Methods for diagnosing and treating cancer by means of the expression status and mutational status of NRF2 and downstream target genes of said gene [P] . US11066709B2 . 2021-07-20

  机译： 通过所述基因的NRF2和下游靶基因的表达状态和突变状态诊断和治疗癌症的方法

• 5. METHODS FOR DIAGNOSING AND TREATING CANCER BY MEANS OF THE EXPRESSION STATUS AND MUTATIONAL STATUS OF NRF2 AND DOWNSTREAM TARGET GENES OF SAID GENE. [P] . 世界知识产权组织专利： WO2018009939A9 . 2019-02-21

  机译： 通过NRF2的表达状态和突变状态以及所述基因的下游靶基因进行诊断和治疗癌症的方法。

• 1. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment [J] . Feng Wu, Min-Jin Wu, Xiao-Lin Zhuge, 国际肝胆胰疾病杂志（英文版） . 2012,第002期
• 2. CT Texture Analysis: A Potential Biomarker for Evaluating KRAS Mutational Status in Colorectal Cancer [J] . Jian Cao, Guorong Wang, Zhiwei Wang, 中国医学科学杂志（英文版） . 2020,第004期
• 3. Treatment and survival status of patients with EGFR mutation-positive stage Ⅳ lung adenocarcinoma： five-year follow-up results in the Ordos Area of Inner Mongolia, China [J] . Gaowa Jin, Wenjuan Wang, Shuqin Deng, 肿瘤学与转化医学（英文） . 2018,第4)期
• 4. Treatment and survival status of patients with EGFR mutation-positive stage Ⅳ lung adenocarcinoma: five-year follow-up results in the Ordos Area of Inner Mongolia, China [J] . Gaowa Jin, Hui Li, Ziyu Lu, 中德临床肿瘤学杂志（英文版） . 2018,第004期
• 5. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: Results of CALGB 89803 [J] . WarrenR.S., AtreyaC.E., NiedzwieckiD., Clinical cancer research: an official journal of the American Association for Cancer Research . 2013,第20期
• 6. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer [J] . Zhang Feng, Zhong Wenhui, Li Honghao, Frontiers in Cell and Developmental Biology . 2021,第a期
• 7. Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases [J] . Fostira F., Konstantopoulou I., Mavroudis D., Clinical Genetics: An International Journal of Genetics in Medicine . 2015,第4期
• 8. Immunologic Treatments for Gastrointestinal Cancers: Current Status and Future Strategies [C] . Elizabeth M. Jaffee Gastrointestinal Cancers Symposium . 2014
• 9. The response of human colorectal xenografts with abnormal Tp53 status to chronomodulated Topotecan and X-radiation treatments [D] . Dhaliwal, Daljit K. 2008
• 10. Individualizing anti-metabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status [O] . Vlad C. Sandulache, Heath D. Skinner, Thomas J. Ow, -1
• 11. Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803 [O] . Robert S. Warren, Chloe E. Atreya, Donna Niedzwiecki, 2013

• 1. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer [J] . Xiang-Bin Wan ,Ai-Qin Wang ,Jian Cao . 世界胃肠病学杂志：英文版 . 2019,第7期
• 2. 癌症的个体化治疗:通过检测KRAS突变状态指导以EGFR为靶点的抗癌药物用药 [C] . . 福建省药学会药剂专业委员会2014年学术年会 . 2014
• 3. KRAS和TP53突变状态与EGFR、ALK阴性非小细胞肺癌化疗疗效的关系及相关分析 [A] . 曹佳欣 . 2019